Drugs / ONVAX-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07637786 | Jun 2026 → Sep 2028 expected | pancreatic adenocarcinoma | Sichuan University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONVAX-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07637786 ↗ |
| Modality | Peptide | “The peptide nanovaccine (ONVAX-01) is administered via subcutaneous (SC) or intradermal (ID) injection” NCT07637786 ↗ |
| Route | Subcutaneous | “administered via subcutaneous (SC)” NCT07637786 ↗ |